| __timestamp | Eli Lilly and Company | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4932500000 | 21226345 |
| Thursday, January 1, 2015 | 5037200000 | 139626 |
| Friday, January 1, 2016 | 5654900000 | 93831530 |
| Sunday, January 1, 2017 | 6070200000 | 79419009 |
| Monday, January 1, 2018 | 4681700000 | 368673 |
| Tuesday, January 1, 2019 | 4721200000 | 477121 |
| Wednesday, January 1, 2020 | 5483300000 | 1895029 |
| Friday, January 1, 2021 | 7312800000 | 8034589 |
| Saturday, January 1, 2022 | 6629800000 | 20443000 |
| Sunday, January 1, 2023 | 7082200000 | 33745000 |
| Monday, January 1, 2024 | 8418299999 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. Eli Lilly and Company, a stalwart in the industry, has consistently managed its cost of revenue, showcasing a steady increase from 2014 to 2023. Notably, their cost of revenue peaked in 2021, marking a 48% rise from 2014. This trend reflects their strategic investments in research and development, aligning with their growth trajectory.
Conversely, Intra-Cellular Therapies, Inc., a burgeoning player, presents a different narrative. Their cost of revenue, though significantly lower, has seen a dramatic increase, particularly between 2016 and 2023, where it surged by over 1,500%. This reflects their aggressive expansion and scaling efforts in a competitive market.
These insights underscore the diverse strategies employed by established and emerging companies in navigating the complexities of the pharmaceutical sector.
Analyzing Cost of Revenue: Eli Lilly and Company and GSK plc
Cost Insights: Breaking Down Eli Lilly and Company and Pfizer Inc.'s Expenses
Cost of Revenue: Key Insights for Eli Lilly and Company and BeiGene, Ltd.
Eli Lilly and Company vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Eli Lilly and Company and Bausch Health Companies Inc.'s Expenses
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Intra-Cellular Therapies, Inc.
Cost of Revenue Trends: Incyte Corporation vs Intra-Cellular Therapies, Inc.
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs Walgreens Boots Alliance, Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Lantheus Holdings, Inc.
Intra-Cellular Therapies, Inc. vs MorphoSys AG: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Intra-Cellular Therapies, Inc. and Bausch Health Companies Inc.'s Expenses
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs Amphastar Pharmaceuticals, Inc.